Form 4: Upstream Bio Executive Adam Houghton Acquires Stock Options
SEC Form 4 Filing
Adam Houghton, Chief Business Officer of Upstream Bio, Inc., was granted stock options for 140,000 shares on February 6, 2025, according to a recent SEC filing.
Summary
- Adam Houghton, Chief Business Officer of Upstream Bio, Inc., filed a Form 4 with the SEC.
- The filing reports a transaction on February 6, 2025, where Houghton acquired stock options for 140,000 shares of Upstream Bio's common stock.
- The exercise price of the options is $8.53 per share.
- The options vest in 48 equal monthly installments starting February 6, 2025, contingent upon Houghton's continued service.
- Allison Ambrose, as Attorney-in-Fact, signed the filing on February 7, 2025, using a substitute power of attorney.
- A substitute power of attorney was put in place on December 19, 2024, appointing Allison Ambrose as substitute attorney-in-fact for Michael Gray, who was originally appointed attorney-in-fact for several individuals including Adam Houghton.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and generally viewed as a positive incentive for executives. There are no explicitly negative aspects in the document.
Positives
- The granting of stock options to a key executive like the Chief Business Officer can be seen as a way to incentivize performance and align their interests with those of the shareholders.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule of the options suggests a four-year commitment from the executive.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract and retain key talent, aligning their interests with the long-term success of the company.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in biotech companies.
- The size of the grant (140,000 shares) and the vesting schedule (4 years) are within typical ranges for similar roles in comparable companies.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options extensively as part of their executive compensation plans.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the Chief Business Officer to drive company growth.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 12/19/24 | Date of substitute power of attorney appointing Allison Ambrose as substitute attorney-in-fact. |
| 02/06/2025 | Date of the stock option grant to Adam Houghton. |
| 02/06/2025 | First vesting date of the stock options. |
| 02/07/2025 | Date of SEC filing (Form 4) signed by Allison Ambrose. |
| 02/05/2035 | Expiration date of the stock options. |
Keywords
stock options, Form 4, Upstream Bio, Adam Houghton, insider trading, SEC filing, beneficial ownership, Allison Ambrose, Michael Gray, power of attorney
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.